Skip to content

Ocular Therapeutix’s Sawhney Discusses Regeneron, FDA

Amar Sawhney, president, CEO, and chairman of Ocular Therapeutix, gives details on his company’s new collaboration with Regeneron to develop a sustained-release formulation of the vascular endothelial growth factor (VEGF) trap aflibercept for the treatment of wet age-related macular degeneration (wet AMD) and other serious retinal diseases.

http://www.businesswire.com/news/home/20161013005405/en/Ocular-Therapeutix%E2%84%A2-Regeneron-Enter-Strategic-Collaboration-Develop

Participant:

Amar Sawhney

Amar Sawhney

Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006, has since served as President and CEO and was elected Chairman of the Board in 2014.

View Full Profile

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.

Scroll To Top